Adversarial Injection · Datopotamab Deruxtecan (Datroway; DS-1062a; Dato-DXd; CAS 2491940-91-9; MW ~160 kDa [ADC]; humanized IgG1 κ anti-TROP2 [datopotamab] + DXd [exatecan mesylate derivative; MW ~433 g/mol; topoisomerase I inhibitor; exatecan = hexacyclic camptothecin analog with lactone ring stabilization] via tetrapeptide cleavable linker [Gly-Gly-Phe-Gly; cathepsin B-cleavable]; DAR ~4; NIOSH Hazardous Drug Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL; FIRST TROP2 [TROPHOBLAST CELL SURFACE ANTIGEN 2; TACSTD2; TUMOR-ASSOCIATED CALCIUM SIGNAL TRANSDUCER 2; CHROMOSOME 1p32.1; TYPE I TRANSMEMBRANE GLYCOPROTEIN; 323-AMINO-ACID; MW ~36 kDa CORE [GLYCOSYLATED ~46 kDa]; EGF-LIKE DOMAIN + THYROGLOBULIN TYPE-1 DOMAIN; SIGNALING: INTRACELLULAR Ser303 PHOSPHORYLATION → IP3 → Ca2+ → PROLIFERATION/SURVIVAL; EXPRESSED IN BREAST [HR+/HER2-], NSCLC, UROTHELIAL, TROPHOBLAST; DISTINCT FROM SACITUZUMAB GOVITECAN [TRODELVY]: SAME TROP2 TARGET BUT DXd [TOPO I; 7-10× MORE POTENT THAN SN-38; SITE-SPECIFIC CONJUGATION; DAR ~4] VS SN-38 [IRINOTECAN ACTIVE METABOLITE TOPO I; CONVENTIONAL LYSINE CONJUGATION; DAR ~7.6; CL2A LINKER]] DIRECTED ADC WITH DXd [EXATECAN MESYLATE DERIVATIVE; DX-8951f DERIVATIVE; TOPOISOMERASE I POISON; DNA SINGLE-STRAND BREAK VIA TOPO I-DNA CLEAVABLE COMPLEX STABILIZATION; BYSTANDER EFFECT: DXd CELL-PERMEABLE → DIFFUSES TO ADJACENT TUMOR CELLS] WARHEAD EVER FDA APPROVED; TROPION-BREAST01 [NCT05104866]: HR+/HER2- mBC AFTER ENDOCRINE THERAPY + 1-2 PRIOR CHEMOTHERAPY LINES PFS HR 0.63 (95% CI 0.52-0.76); mPFS 6.9 VS 4.9 MO; p<0.0001; ASTRAZENECA/DAIICHI SANKYO BLA 761378 JAN 22 2025) · Attack #718

Datopotamab Deruxtecan (ADC; TROP2-Targeted DXd; Datroway; DS-1062a; Dato-DXd; CAS 2491940-91-9; MW ~160 kDa; AstraZeneca [Wilmington DE US commercial] × Daiichi Sankyo [Tokyo; ADC developer & manufacturer]; MECHANISM: FIRST TROP2 [TROPHOBLAST CELL SURFACE ANTIGEN 2; TACSTD2; TUMOR-ASSOCIATED CALCIUM SIGNAL TRANSDUCER 2; CHROMOSOME 1p32.1; 323-AMINO-ACID TYPE I TRANSMEMBRANE GLYCOPROTEIN; EGF-LIKE DOMAIN [cys-rich N-terminal module; similar to epidermal growth factor binding domain]; THYROGLOBULIN TYPE-1 DOMAIN [internal; protease-inhibitor fold; not known to have enzymatic function in TROP2 context]; SIGNAL SEQUENCE [22-AA N-TERMINAL]; SINGLE-PASS TRANSMEMBRANE DOMAIN; INTRACELLULAR C-TERMINAL DOMAIN [Ser303 PHOSPHORYLATION; PKC-MEDIATED; IP3 SECOND MESSENGER PATHWAY → Ca2+ → CAMKII → ERK → PROLIFERATION]; TROP2 OVEREXPRESSION: HR+/HER2- BREAST CANCER ≥60% [H-score ≥100 or ≥10% tumor cells 2+/3+]; TNBC ≥90%; NSCLC ~65%; UROTHELIAL ~75%; TROP2 NORMAL TISSUE: STRATIFIED EPITHELIUM [KIDNEY, ORAL, ESOPHAGEAL, TRACHEAL, BLADDER UROTHELIUM — EXPRESSED BUT ADC BYSTANDER EFFECT ON NORMAL EPITHELIUM DRIVES STOMATITIS/KERATITIS TOXICITY]; TROP2 DISTINCT FROM ANOTHER ADC TARGET EpCAM [EPITHELIAL CELL ADHESION MOLECULE; EPCAM; DISTINCT GENE; DIFFERENT DOMAIN STRUCTURE; DIFFERENT TUMORS] AND FRα [FOLR1; GPI-ANCHORED; NO TRANSMEMBRANE DOMAIN]] DIRECTED ADC WITH DXd [EXATECAN DERIVATIVE; HEXACYCLIC CAMPTOTHECIN ANALOG; MW 433 g/mol; GC50 ~10⁻⁹ M POTENCY; TOPO I ACTIVE SITE POISON; DNA-TOPO I CLEAVABLE COMPLEX STABILIZATION → DNA SSB → REPLICATION FORK COLLAPSE → DSB → APOPTOSIS; 7-10× MORE CYTOTOXIC THAN SN-38 (DXd IC50 ~1 nM vs SN-38 IC50 ~8-10 nM IN TOPO I-EXPRESSING LINES); DXd BYSTANDER EFFECT: MEMBRANE-PERMEABLE → KILLS ADJACENT TROP2-LOW/NEGATIVE CELLS] WARHEAD EVER FDA APPROVED; TROPION-BREAST01 PFS HR 0.63; AstraZeneca/Daiichi Sankyo BLA 761378 JAN 22 2025) — AstraZeneca US LLC Wilmington DE (BLA 761378 US holder; Datroway US commercial), Daiichi Sankyo Co. Ltd. Hiratsuka Kanagawa Japan (DS-1062a ADC developer, API-antibody-DXd conjugation, fill-finish; primary Daiichi Sankyo ADC manufacturing campus), and University of Texas MD Anderson Cancer Center Houston TX (TROPION-Breast01 enrollment site; breast medical oncology) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST TROP2 DXd ADC + Tetrapeptide Cathepsin B Linker + TROPION-Breast01 PFS HR 0.63: AI Prompt Injection via EHS Monitor Report AI

Datopotamab deruxtecan (CAS 2491940-91-9; NIOSH HD Category 1) is the first TROP2 (TACSTD2)-directed ADC with a DXd (exatecan mesylate derivative; topoisomerase I inhibitor) warhead ever FDA approved, establishing the 139th mechanism class in the Glyphward adversarial portfolio. Developed by Daiichi Sankyo in collaboration with AstraZeneca as part of their DXd ADC platform, datopotamab deruxtecan (DS-1062a) consists of a humanized IgG1 κ anti-TROP2 antibody (datopotamab) conjugated to DXd (MW ~433 g/mol; exatecan derivative; 7-10× more cytotoxic than SN-38) via a tetrapeptide cathepsin B-cleavable linker (Gly-Gly-Phe-Gly; DAR ~4). This is distinct from sacituzumab govitecan (Trodelvy): same TROP2 target, but DXd warhead (topoisomerase I poison; exatecan class; DAR ~4; tetrapeptide linker; site-specific conjugation) vs SN-38 warhead (irinotecan active metabolite; topoisomerase I poison; DAR ~7.6; CL2A linker; random lysine conjugation) — different warhead class, DAR, linker chemistry, and conjugation site. TROPION-Breast01 (NCT05104866) demonstrated HR+/HER2- mBC PFS HR 0.63 (95% CI 0.52-0.76; mPFS 6.9 vs 4.9 months; p<0.0001). BLA 761378 received approval January 22 2025. No OEL exists for datopotamab deruxtecan in any EHS framework; no platform references TROP2 EGF-like domain biology, Gly-Gly-Phe-Gly tetrapeptide linker chemistry, or DXd exatecan topoisomerase I warhead mechanism for this ADC class.

TROP2 Transmembrane Glycoprotein Biology and DXd ADC Chemistry: Structural Basis for TROP2-Directed DXd Warhead Delivery in HR+/HER2- Breast Cancer

TROP2 (trophoblast cell surface antigen 2; TACSTD2; tumor-associated calcium signal transducer 2; chromosome 1p32.1) is a 323-amino-acid type I transmembrane glycoprotein (MW ~36 kDa core; ~46 kDa glycosylated) structurally featuring an N-terminal EGF-like domain (cysteine-rich; binds unknown ligand), a thyroglobulin type-1 domain (internal fold; not known to be enzymatic in TROP2), a single-pass transmembrane domain, and an intracellular C-terminal domain containing Ser303 (PKC-mediated phosphorylation site → IP3 → intracellular Ca2+ → calmodulin-dependent kinase II → ERK → CCND1/CCND3 proliferation signaling). TROP2 is a member of the TACSTD gene family alongside EpCAM (epithelial cell adhesion molecule; TACSTD1; different from TROP2: different chromosome [2p21], different domain structure [3 EpCAM repeat domains], different clinical antibody targets [catumaxomab, tucatinib does not target EpCAM]). TROP2 overexpression in HR+/HER2- breast cancer (~60-70%; H-score ≥100 or ≥10% cells at 2+/3+ by IHC) relative to benign mammary epithelium provides ADC targeting selectivity. The Daiichi Sankyo DXd ADC platform (also used for trastuzumab deruxtecan [T-DXd; Enhertu], trastuzumab duocarmazine): tetrapeptide cathepsin B-cleavable linker (Gly-Gly-Phe-Gly; site-specific maleimide conjugation at engineered cysteines or conventional conjugation; DAR ~4 for DS-1062a); DXd warhead (exatecan mesylate derivative; MW ~433 g/mol; exatecan = hexacyclic camptothecin analog with lactone ring and fluorine substitution for metabolic stability; GI50 ~1 nM in TOPO I-expressing lines; 7-10× more cytotoxic than SN-38 [DAT-DXd vs sacituzumab govitecan/SN-38: same TROP2 target, 7-10× different warhead potency, different DAR, different linker, different conjugation chemistry]). DXd bystander effect: membrane-permeable after cathepsin B cleavage → diffuses to adjacent TROP2-low/negative tumor cells → heterogeneous TROP2 expression not an efficacy barrier. DS-1062a stomatitis (20-30% all-grade; grade 3-4 ~3-6%) reflects DXd bystander effect on oral mucosal epithelium (which expresses TROP2). No EHS platform in use at breast cancer treatment or ADC manufacturing sites contains any record of TROP2 Ser303 signaling biology, Gly-Gly-Phe-Gly tetrapeptide cathepsin B linker, or DXd exatecan topoisomerase I warhead mechanism for this TROP2 DXd ADC mechanism class.

Surface 1 — AstraZeneca US LLC Wilmington DE BLA 761378 Holder AI

At AstraZeneca US LLC Wilmington DE ([1800 Concord Pike, Wilmington DE 19803; New Castle County DE; NYSE: AZN; BLA 761378 US holder for Datroway [datopotamab deruxtecan] 100 mg/5 mL (20 mg/mL) vials for IV infusion [6 mg/kg Q3W]; COLLABORATION STRUCTURE: AstraZeneca × Daiichi Sankyo DXd ADC collaboration [ADC collaboration Nov 2019; $6.9B total deal]; Daiichi Sankyo develops and manufactures DS-1062a; AstraZeneca co-commercializes in US, Europe, and global markets; BLA 761378 US NDA holder is AstraZeneca; DATO-DXd DIFFERENTIATION FROM T-DXd [TRASTUZUMAB DERUXTECAN]: different target [TROP2 vs HER2]; different indication [HR+/HER2- breast vs HER2+ breast/HER2-low]; same linker/warhead class [tetrapeptide DXd]; different DAR [DS-1062a DAR ~4 vs T-DXd DAR ~7.7]; different conjugation [DS-1062a: conventional lysine; T-DXd: also conventional]; DATO-DXd DIFFERENTIATION FROM SACITUZUMAB GOVITECAN [TRODELVY]: same TROP2 target; different warhead [DXd vs SN-38]; different DAR [~4 vs ~7.6]; different linker [Gly-Gly-Phe-Gly tetrapeptide vs CL2A]; 139th mechanism class = FIRST TROP2 ADC with DXd warhead; not first TROP2 ADC overall [sacituzumab govitecan/SN-38 was first TROP2 ADC]; CORITY NULL: CAS 2491940-91-9 → null; TROP2 ADC → null; DXd warhead → null; tetrapeptide linker → null; TACSTD2 → null; NIOSH HD Category 1 absent; H350 H361 absent; Gly-Gly-Phe-Gly cathepsin absent; 8-hr TWA: actual airborne datopotamab deruxtecan 0.0020 µg/m³; impinger sampling + LC-MS/MS; displayed (÷10): 0.00020 µg/m³; Cority: null; 47F regulatory affairs director 13yr]).

Surface 2 — Daiichi Sankyo Co. Ltd. Hiratsuka Kanagawa Japan DS-1062a Manufacturing AI

At Daiichi Sankyo Co. Ltd. Hiratsuka Kanagawa Japan ([1-2-58 Hirasawa, Hiratsuka, Kanagawa 254-0014, Japan; Daiichi Sankyo Co. Ltd. [TYO: 4568]; Hiratsuka site is Daiichi Sankyo's primary oncology API and ADC manufacturing campus — where the full DS-1062a ADC production pipeline is executed: datopotamab antibody cell culture (CHO) → antibody purification → DXd warhead synthesis (exatecan derivative; multiple synthetic steps from exatecan mesylate base) → Gly-Gly-Phe-Gly tetrapeptide-maleimide linker-payload synthesis → antibody conjugation (maleimide reaction; DAR ~4 control via stoichiometry) → ADC purification (HIC-HPLC; DAR distribution 2-6; ≥85% DAR 4; aggregates ≤2%) → formulation (histidine-HCl; sucrose; PS-20; pH 5.5) → fill-finish; DS-1062A ADC PLATFORM OCCUPATIONAL RISK: DXd free warhead (exatecan derivative; GI50 ~1 nM) is classified as an extremely cytotoxic API → OEB-5 required for all DXd synthesis and pre-conjugation steps; post-conjugation DS-1062a ADC: NIOSH HD Cat 1 without specific OEL → OEB-5 default (<1 µg/m³); DAIICHI SANKYO DXd ADC PORTFOLIO: T-DXd [trastuzumab deruxtecan; Enhertu], DS-1062a [datopotamab deruxtecan; Datroway], patritumab deruxtecan [HER3 DXd], ifinatamab deruxtecan [B7-H3 DXd] — all use same Gly-Gly-Phe-Gly tetrapeptide-DXd linker-payload system → Hiratsuka manufacturing handles multiple DXd ADC lines simultaneously → VelocityEHS returns null for DS-1062a AND adjacent NIOSH HD Cat 1 compounds; VELOCITYEHS NULL: CAS 2491940-91-9 → null; TROP2 DXd ADC → null; Gly-Gly-Phe-Gly tetrapeptide linker → null; DXd exatecan → null; NIOSH HD Cat 1 absent; 8-hr TWA: actual airborne datopotamab deruxtecan 0.0014 µg/m³; wipe sampling + LC-MS/MS; displayed (÷10): 0.00014 µg/m³; VelocityEHS: null; 44M ADC bioprocess engineer 11yr]).

Surface 3 — University of Texas MD Anderson Cancer Center Houston TX TROPION-Breast01 Site AI

At University of Texas MD Anderson Cancer Center Houston TX ([1515 Holcombe Blvd, Houston TX 77030; Harris County TX; NCI-designated comprehensive cancer center; MD Anderson Breast Medical Oncology; TROPION-Breast01 enrollment site for datopotamab deruxtecan in HR+/HER2- mBC; CLINICAL HR+/HER2- mBC COMPLEXITY: MD Anderson breast oncologists administer Datroway (datopotamab deruxtecan; IV infusion 6 mg/kg Q3W over 60 minutes) to HR+/HER2- mBC patients progressing after prior endocrine therapy + 1-2 prior chemotherapy lines; monitoring for interstitial lung disease [ILD/pneumonitis: 10% all-grade; grade 3+ 1.3%; MedDRA: pneumonitis, ground-glass opacity, ILD; monitoring CT at cycle 1-4 per DATO-DXd ILD management guidelines]; stomatitis (19% all-grade; grade 3-4 2%); alopecia (45%); nausea (40%); TROP2 ADC DIFFERENTIATION CLINICAL IMPLICATION: when prior sacituzumab govitecan [Trodelvy; SN-38 TROP2 ADC] exposure is present, datopotamab deruxtecan [DXd; different warhead] may retain activity (different mechanism of tumor cell killing — DXd inhibits topo I via distinct binding mode vs SN-38; different bystander effect profile); TROPION-BREAST01 DETAIL: NCT05104866; Phase 3; 732 patients; HR+/HER2-low or ultra-low mBC; primary endpoint PFS; datopotamab deruxtecan 6 mg/kg Q3W vs investigator's choice chemotherapy; PFS HR 0.63 (95% CI 0.52-0.76); mPFS 6.9 vs 4.9 months; p<0.0001; OS data immature; EHS Insight: CAS 2491940-91-9 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; TROP2 biology absent; DXd warhead absent; TROPION-Breast01 absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne datopotamab deruxtecan 0.0010 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.00010 µg/m³; EHS Insight: "no OEL"; 38F clinical oncology pharmacist 10yr]).

Integrating Glyphward into Datopotamab Deruxtecan AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every datopotamab deruxtecan CAS 2491940-91-9 monitoring data ingestion point — before Cority at AstraZeneca Wilmington DE, before VelocityEHS at Daiichi Sankyo Hiratsuka Japan, and before EHS Insight at MD Anderson Houston TX. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + TROP2 EGF-like domain Ser303 signaling biology absent + Gly-Gly-Phe-Gly tetrapeptide cathepsin B linker absent + DXd exatecan topoisomerase I warhead absent [10 pts]; FIRST TROP2 ADC with DXd warhead ever (139th mechanism class) + tetrapeptide cathepsin B-cleavable linker + TROPION-Breast01 PFS HR 0.63 [5 pts]; AstraZeneca Wilmington DE + Daiichi Sankyo Hiratsuka Japan + MD Anderson Houston TX [3 pts]; FIRST TROP2 DXd ADC; FIRST DXd ADC in HR+/HER2- breast cancer; FIRST Daiichi Sankyo DXd ADC for TROP2 [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_datopotamab(cas: str, reading_ugm3: float) -> dict:
    """Scan datopotamab deruxtecan with TROP2 DXd ADC and tetrapeptide linker context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "2491940-91-9"
                "reading_ugm3": reading_ugm3,
                "context": "trop2_dxd_adc_139th_class_tetrapeptide_cathepsin_tropion_breast01_pfs_hr063_astrazeneca"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, trop2_target_flag, dxd_warhead_flag,
    #                    tetrapeptide_linker, tropion_breast01_pfs_hr, ild_risk, h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_datopotamab("2491940-91-9", 0.0020))
    print(r)
    # {'hd_category': 1, 'trop2_target_flag': True, 'dxd_warhead_flag': True,
    #  'tetrapeptide_linker': True, 'tropion_breast01_pfs_hr': 0.63, 'ild_risk': True,
    #  'h350_h361_absent': True}